Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/12951
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ellul, Ian C. | - |
dc.date.accessioned | 2016-10-13T12:18:50Z | - |
dc.date.available | 2016-10-13T12:18:50Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Ellul, Ian, C. (2012). Editor's word : money matters. The Synapse, (5), 3 | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar//handle/123456789/12951 | - |
dc.description.abstract | It has been calculated that to market a novel drug a pharmaceutical company has to fork out up to a staggering Euro10,000,000,000 (Source: www. forbes.com/forbes/2012/0312/strategiespharmaceuticals- lilly-stagger-costinventing- new-drugs.html). It is also becoming increasingly difficult to find new moieties and this is driving the expenses further up. Furthermore, the recession does not help. However as the saying goes, necessity is the mother of invention. And one Darwinian lesson which mankind has learnt is, precisely, how to adapt. In fact pharma companies are increasingly starting to explore alternatives to increase profits. After all, profit making is a very simple formula. You either increase income from sales or decrease production costs and examples to reach these goals range from additive printing to nanotechnology to medicinal chemistry. Such techniques are being discovered or rather, rediscovered, as methods by which one can either make existing medicines cheaper, thus making them more accessible resulting in increased sales, or more effective. This editorial will discuss two novel, albeit different strategies to produce more effective medicine | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Medical Portals Ltd. | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Pharmaceutical industry | en_GB |
dc.subject | Drug development | en_GB |
dc.subject | Medical care -- Cost effectiveness | en_GB |
dc.title | Editor's word : money matters | en_GB |
dc.title.alternative | Money matters | en_GB |
dc.title.alternative | Editorial [The Synapse, (5)] | en_GB |
dc.type | editorial | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
Appears in Collections: | The Synapse, Issue 5 The Synapse, Issue 5 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Money matters - editorial.pdf | 603.6 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.